Online inquiry

IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14039MR)

This product GTTS-WQ14039MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14039MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11827MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-4280
GTTS-WQ7811MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ1723MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ADC-1013
GTTS-WQ4072MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI 836
GTTS-WQ3513MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ8875MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ4178MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ9087MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMCgp100
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW